Related Experiment Video

Updated: Aug 17, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

10.8K

Novartis's Kymriah: Harnessing Immune System Comes With Worry About Reining in Costs

Thomas Morrow

    Managed Care (Langhorne, Pa.)
    |October 26, 2017
    PubMed

    Abstract:

    FDA approval of the CAR T-cell therapy for leukemia could usher in an era of genetically engineered, individually tailored immunotherapies. But tap those brakes. Long-term results are in short supply-and there's that $475,000 price tag. Or is it a $750,000 price tag?

    Keywords:
    Tomorrow’s Medicine

    More Related Videos

    Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
    05:54

    Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

    Published on: September 5, 2018

    9.1K
    Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
    07:09

    Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

    Published on: January 7, 2019

    8.0K

    Related Experiment Videos

    Last Updated: Aug 17, 2026

    Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
    08:34

    Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

    Published on: April 13, 2015

    10.8K
    Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening
    05:54

    Generation of High-Throughput Three-Dimensional Tumor Spheroids for Drug Screening

    Published on: September 5, 2018

    9.1K
    Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
    07:09

    Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

    Published on: January 7, 2019

    8.0K

    Related Concept Videos

    Hybridoma Technology01:31

    Hybridoma Technology

    Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
    Hybridoma Selection
    Commonly used fusion techniques — electroporation, polyethylene glycol...

    Articles linked to this work by shared authors, journal, and citation graph.

    Guiding the Molnupiravir Tablet Formulation Using Physiologically Based Biopharmaceutics Modeling and Successfully Establishing Dissolution Safe Space.

    The AAPS journal·2026

    Observations of trash in the deep tropical Atlantic and Caribbean Sea.

    Marine pollution bulletin·2024

    Improving outcomes and managing costs in idiopathic pulmonary fibrosis.

    The American journal of managed care·2019

    Multidrug Resistant HIV Drug Lauded, But Clinical Foundation Not Very Deep.

    Managed care (Langhorne, Pa.)·2018

    New Test for Diagnosing Insulin Resistance Could Turn the Tide Against Diabetes.

    Managed care (Langhorne, Pa.)·2018

    Hemlibra's Remarkable Efficacy A Beacon For Hemophilia Patients.

    Managed care (Langhorne, Pa.)·2018

    Thanks to CMS Rule Change, MA Takes SDOH to a Whole New Level.

    Managed care (Langhorne, Pa.)·2019

    Hail, Not Frail! MA's Wellness Reach Expands.

    Managed care (Langhorne, Pa.)·2019

    To Be Continued:The Search for a Cure for HIV.

    Managed care (Langhorne, Pa.)·2019

    Once-a-day HIV Treatment: Pricey But Perhaps Worth It.

    Managed care (Langhorne, Pa.)·2019

    In Trump, HIV/AIDS Groups Find an Ally Who's Tough To Love.

    Managed care (Langhorne, Pa.)·2019

    Air Ambulance Turbulence: Consolidation, Cost Shifting, and Surprise Billing.

    Managed care (Langhorne, Pa.)·2019

    Eplontersen with and without background transthyretin stabilizers in transthyretin amyloid cardiomyopathy: secondary analysis of a phase 3, randomized controlled trial.

    Nature medicine·2026

    SARS-CoV-2 management strategies in B-Cell-depleted people with multiple sclerosis: from prevention to antiviral treatment.

    Expert review of clinical immunology·2026

    Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy.

    ERJ open research·2026

    Integrated multi-omics analysis indicates MARCO and ZBTB20 as candidate biomarkers in rheumatoid arthritis and tuberculosis.

    Frontiers in immunology·2026

    Anti-Trop2-Guided Liposomes Restore Methotrexate Sensitivity in Chemoresistant Gestational Trophoblastic Neoplasia.

    International journal of nanomedicine·2026

    Sequence-based artificial intelligence-guided inhibitory peptides to counteract AAV neutralizing antibodies in gene therapy.

    Molecular therapy. Advances·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us